share_log

藥明康德:海外監管公告

WUXI APPTEC: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

Hong Kong Stock Exchange ·  Apr 29 09:18
Summary by Moomoo AI
药明康德於2024年4月29日召開第三屆監事會第八次會議,會議由監事會主席Harry Liang He(贺亮)主持,並通過了《關於公司2024年第一季度報告的議案》。該報告的編制程序符合相關法律法規及《公司章程》的要求,且內容真實、準確、完整地反映了公司2024年1-3月的經營管理和財務狀況,無虛假記載、誤導性陳述或重大遺漏。該季度報告已於同日在上海證券交易所網站及指定媒體公開披露。
药明康德於2024年4月29日召開第三屆監事會第八次會議,會議由監事會主席Harry Liang He(贺亮)主持,並通過了《關於公司2024年第一季度報告的議案》。該報告的編制程序符合相關法律法規及《公司章程》的要求,且內容真實、準確、完整地反映了公司2024年1-3月的經營管理和財務狀況,無虛假記載、誤導性陳述或重大遺漏。該季度報告已於同日在上海證券交易所網站及指定媒體公開披露。
Ming Kand Pharmaceutical held the eighth meeting of the Third Supervisory Board on 29 April 2024, chaired by Chairman of the Board Harry Liang He (Heiliang), and passed the “Motion on the Company's First Quarter Report 2024”. The reporting process complies with the requirements of the relevant laws and regulations and the Articles of Association and the contents of the Company truthfully, accurately and completely reflect the Company's management and financial situation in March 2024, without false records, misleading statements or material omissions. The quarterly report was publicly disclosed on the Shanghai Stock Exchange's website and designated media on the same day.
Ming Kand Pharmaceutical held the eighth meeting of the Third Supervisory Board on 29 April 2024, chaired by Chairman of the Board Harry Liang He (Heiliang), and passed the “Motion on the Company's First Quarter Report 2024”. The reporting process complies with the requirements of the relevant laws and regulations and the Articles of Association and the contents of the Company truthfully, accurately and completely reflect the Company's management and financial situation in March 2024, without false records, misleading statements or material omissions. The quarterly report was publicly disclosed on the Shanghai Stock Exchange's website and designated media on the same day.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more